Page 3 of 5 
6. ALTERNATE PROCEDURES OR TREATMENTS: My participation in this marking study 
is totally optional and the treatment on TIL/PBL protocols may be carried out whether or not I 
participate in the marking study. I may decline to have marking, but still have the TIL/PBL 
treatment. 
UNDERSTANDING OF PARTICIPANTS 
7. I have been given an opportunity to ask any questions concerning the investigational regimen 
involved and the investigator has willingly replied to my inquiries. This investigational treatment 
program will be administered under the above numbered, titled and described clinical research 
protocol at this institution. I hereby authorize Dr. , the attending 
physician/investigator and designated associates to administer this investigational treatment 
program. 
8. I have been told and understand that my participation is voluntary. I may decide not to 
participate, or withdraw my consent and discontinue my participation at any time. Such action 
will be without prejudice and there shall be no penalty or loss of benefits to which I may 
otherwise be entitled, and I will continue to receive treatment by my physician at this institution. 
Should I decide not to participate or withdraw my consent from participation in this clinical 
research, I have been advised that I should discuss the consequences or effects of my decision 
with my physician. 
In addition, I understand that the investigator may discontinue the clinical researching study if, 
in the sole opinion and discretion of the investigator, the study or treatment offers me little or 
no future benefit, or the supply of medication ceases to be available or other causes prevent 
continuation of the clinical research study. The investigator will notify me should such 
circumstances arise and my physician will advise me about available treatment which may be of 
benefit at that time. 
I will be informed of any new findings developed during the course of this clinical research 
study, which may relate to my willingness to continue participation in the study. 
9. I have been assured that confidentiality will be preserved except that qualified monitors from 
the Food and Drug Administration may review my records where appropriate and necessary. 
My name will not be revealed in any reports or publications resulting from this study, without 
my expressed consent. 
HSPC #91-10-442 
Date of expiration 
[562] 
Recombinant DNA Research, Volume 15 
